Loss of ZNF516 protein expression is related with HR-HPV infection and cervical preneoplastic lesions
dc.creator | Ili C. | |
dc.creator | Lopez J. | |
dc.creator | Buchegger K. | |
dc.creator | Riquelme I. | |
dc.creator | Retamal J. | |
dc.creator | Zanella L. | |
dc.creator | Mora-Lagos B. | |
dc.creator | Vivallo C. | |
dc.creator | Roa J.C. | |
dc.creator | Brebi P. | |
dc.date.accessioned | 2020-09-02T22:20:35Z | |
dc.date.accessioned | 2022-11-08T20:23:35Z | |
dc.date.available | 2020-09-02T22:20:35Z | |
dc.date.available | 2022-11-08T20:23:35Z | |
dc.date.created | 2020-09-02T22:20:35Z | |
dc.date.issued | 2019 | |
dc.identifier | 299, 4, 1099-1108 | |
dc.identifier | 09320067 | |
dc.identifier | https://hdl.handle.net/20.500.12728/4930 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/5144898 | |
dc.language | en | |
dc.publisher | Springer Verlag | |
dc.subject | Cervical cancer | |
dc.subject | Human papillomavirus | |
dc.subject | Immunohistochemistry | |
dc.subject | Ki-67 | |
dc.subject | p16 | |
dc.subject | ZNF516 | |
dc.subject | biological marker | |
dc.subject | Ki 67 antigen | |
dc.subject | protein p16 | |
dc.subject | unclassified drug | |
dc.subject | zinc finger protein | |
dc.subject | ZNF516 protein | |
dc.subject | DNA binding protein | |
dc.subject | tumor marker | |
dc.subject | ZNF516 protein, human | |
dc.subject | adolescent | |
dc.subject | adult | |
dc.subject | aged | |
dc.subject | Article | |
dc.subject | assay | |
dc.subject | cancer risk | |
dc.subject | clinical feature | |
dc.subject | clinical outcome | |
dc.subject | controlled study | |
dc.subject | disease association | |
dc.subject | early diagnosis | |
dc.subject | female | |
dc.subject | genotype | |
dc.subject | histopathology | |
dc.subject | human | |
dc.subject | human tissue | |
dc.subject | immunohistochemistry | |
dc.subject | major clinical study | |
dc.subject | papillomavirus infection | |
dc.subject | protein expression | |
dc.subject | retrospective study | |
dc.subject | reverse line blot assay | |
dc.subject | squamous intraepithelial lesion of the cervix | |
dc.subject | uterine cervix biopsy | |
dc.subject | uterine cervix carcinoma | |
dc.subject | uterine cervix carcinoma in situ | |
dc.subject | chemistry | |
dc.subject | complication | |
dc.subject | middle aged | |
dc.subject | papillomavirus infection | |
dc.subject | precancer | |
dc.subject | uterine cervix tumor | |
dc.subject | very elderly | |
dc.subject | virology | |
dc.subject | young adult | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Biomarkers, Tumor | |
dc.subject | DNA-Binding Proteins | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Middle Aged | |
dc.subject | Papillomavirus Infections | |
dc.subject | Precancerous Conditions | |
dc.subject | Retrospective Studies | |
dc.subject | Uterine Cervical Neoplasms | |
dc.subject | Young Adult | |
dc.title | Loss of ZNF516 protein expression is related with HR-HPV infection and cervical preneoplastic lesions | |
dc.type | Article |